



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFW

In re Applicant:

Hadi ASLAN et al

Serial No.: 10/520,271

Filed: January 14, 2005

For: METHODS OF IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE REPAIR AND FORMATION

Examiner: WEHBE, ANNE MARIE SABRINA

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted

Marlin O. Morinhan

Martin D. Moynihan
Registration No. 40,338

Dated: December 15, 2005



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	5	PCT WO 93/00050	07-7-1993	Ron et al.		
Examiner Signature				Date Considered		

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ ⁵

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	Substitute for form 1449A/PTO			Complete if Known	
				Application Number	10/520,271
				Filing Date	January 14, 2005
				First Named Inventor	Hadi ASLAN et al
				Group Art Unit	1633
				Examiner Name	WEHBE, ANNE MARIE SABRINA
2	Of	3	Attorney Docket Number	28921	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	6	Clarke et al. "Mesenchymal Cell Precursors From Human Bone Marrow Have A Phenotype That Is Distinct From Cultured Mesenchymal Cells and Are Exclusively Present in A Small Subset of CD451° SH2+ Cells", Blood, 98(11 Part 1): 85a, 2001. Abstract # 355.			
	7	Quirici et al. "Isolation of Bone Marrow Mesenchymal Stem Cells by Anti-Nerve Growth Factor Receptor Antibodies", Experimental Hematology, 30(7): 783-791, 2000.			
	8	Devine et al. "Mesenchymal Stem Cells Are Capable of Homing to the Bone Marrow of Non-Human Primates Following Systemic Infusion", Experimental Hematology, 29(2): 244-255, 2001.			
	9	Caplan et al. "Mesenchymal StemCells: Building Block for Molecular Medicine in the 21st Cebtury", Trens in Molecular Medicine, 7(6): 259-264, 2001.			
	10	Gronthos et al. "The Growth Factor Requirements of STRO-1- Human Bone Marrow Stromal Precursors Serum-Deprived Conditions In Vitro", Blood, 85(4): 992-940, 1995.			
	11	Fridenshtein "Stromal Bone Marrow Cells and the Hematopoietic Microenvironment", Arkh Patol, 44(10): 3-11, 1982. Abstract.			
	12	Haynesworth et al. "Characterization of Cells with Osteogenic Potential from Human Marrow", Bone, 13: 81-88, 1992.			
	13	Horowitz et al. "Transplantability and Therapeutic Effects of Bone Marrow-Derived Mesenchymal Cells in Childern with Osteogenesis Imperfecta", Nature Medicine, 5(3): 309-313, 1999.			
	14	Kadiyala et al. "Culture Expanded Canine Mesenchymal Stem Cells Possess Osteochondrogenic Potential In Vivo and In Vitro", Cell Transplantation, 6(2): 125-134, 1997.			
	15	Krebsbach et al. "Repair of Craniotomy Defects Using Bone Marrow Stromal Cells", Transplantation, 66(10): 1272-1278, 1998.			
	16	Keunmyoung et al. "Human Mesenchymal Stem Cells MaintainTransgene Expression during Expansionand Differentiation", Molecular Therapy, 3(6), 2001.			
	17	Liechty et al. "Human mesenchymal stem cells engraft and demonstrate sitespecific differentiation after in utero transplantation in sheep", Nature Medicine, 6(11): 1282-1286, 2000.			
	18	Mackay et al. "Chondrogenic Differentiation of Cultured Human Mesenchymal Stem Cells from Marrow", Tissue Engineering, 4(4): 415-428, 1998.			
	19	Majumdar et al. "Isolation, Characterization, and Chondrogenic Potential of Human Bone Marrow-Derived Multipotential Stromal Cells, Journal of Cellular Physiology, 185: 98-106, 2000.			
	20	Majumdar et al. "Cutting Edge Communication - Human Marrow-Derived Mesenchymal Stem Cells (MSCs) Express Hematopoietic Cytokines and Support Long-Term Hematopoiesis when Differntiated Toward Stromal and Osteogenic Lineages", Journal of Hematotherapy & Stem Cell Research, 9: 841-848, 200.			
	21	Pittenger etal. "Multilineage Potential of Adult Human Mesenchymal Stem Cells", Science, 284: 143-147, 1999.			
	22	Toma et al. "Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart", Circulation, 1/8: 93-98, 2002.			
	23	Turgeman et al. "Engineered Human Mesenchymal Stem cells: a Novel Platform for Skeletal Cell Mediated Gene Therapy", The Journal of Gene Medicine, 3: 240-251, 2001.			

	24	Yoo et al. "The Cohondrogenic Potential of Human Bone-Marrow-Derived Mesenchymal Progenitor Cells", Journal of Bone and Joint Surgery, 80-A(12): 1745-1757, 1998.	
	25	Young et al. "Use of Mesenchymal Stem Cells in a Collagen Matrix for Achilles Tendon Repair", Journal of the Orthopaedic Research, 16: 406-413, 1998.	
	26	Pittenger et al. "Human Mesenchymal Stem Cells Can Be Directed Into chondrocytes, Adipocytes and Osteocytes" Mol. Biol. Cell. 1996 &:305a. - Abstract only.	

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.